GE And Shanghai Pulmonary Hospital Jointly Develop Diagnostics For Pneumoconiosis
This article was originally published in PharmAsia News
Executive Summary
GE China's R&D center recently signed an agreement with Shanghai Pulmonary Hospital to jointly develop CAD techniques which can automatically screen and distinguish diseased and normal human thoracic X-ray images. This technique, which greatly decreases the time and cost for pneumoconiosis checkup, will make examinations accessible to more workers, helping in the prevention and treatment of China's leading occupational disease. Current methods are costly and not very effective, resulting in millions of at-risk local workers unscreened. The two partners will also apply the new technique to the field of digital X-ray and simulation X-ray. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.